Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

NCT05176925 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped The trial was terminated per sponsor recommendation

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Tislelizumab
DRUG: Sitravatinib

Sponsor

Fudan University